Skinvisible, Inc. (SKVI) — SEC Filings
Skinvisible, Inc. (SKVI) — 12 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 6 10-Q, 4 8-K, 2 10-K.
View Skinvisible, Inc. on SEC EDGAR
Overview
Skinvisible, Inc. (SKVI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: SKINVISIBLE, INC. (SKVI) reported a net loss of $805,677 for the nine months ended September 30, 2025, a slight improvement from the $880,425 net loss in the prior-year period. Revenue remained flat at $15,000 for both the three and nine months ended September 30, 2025 and 2024, indicating no growth
Sentiment Summary
Across 12 filings, the sentiment breakdown is: 2 bearish, 10 neutral. The dominant filing sentiment for Skinvisible, Inc. is neutral.
Filing Type Overview
Skinvisible, Inc. (SKVI) has filed 6 10-Q, 2 10-K, 4 8-K with the SEC between Apr 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (12)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 13, 2025 | 10-Q | Skinvisible's Cash Dries Up Amidst Mounting Losses, Going Concern Warning Issued | high |
| Aug 13, 2025 | 10-Q | Skinvisible's Cash Dries Up Amidst Mounting Liabilities | high |
| May 14, 2025 | 10-Q | Skinvisible, Inc. Files Q1 2025 10-Q | medium |
| Apr 14, 2025 | 10-K | Skinvisible, Inc. Files 2024 10-K | medium |
| Jan 23, 2025 | 8-K | Skinvisible, Inc. Files 8-K Report | low |
| Nov 19, 2024 | 10-Q | Skinvisible, Inc. Files Q3 2024 10-Q | medium |
| Oct 3, 2024 | 8-K | Skinvisible, Inc. Files 8-K with Corporate Updates | low |
| Aug 15, 2024 | 10-Q | Skinvisible, Inc. Files Q2 2024 10-Q | medium |
| Jun 4, 2024 | 8-K | Skinvisible Reports Unregistered Equity Sales | medium |
| May 29, 2024 | 8-K | Skinvisible, Inc. Files 8-K | low |
| May 15, 2024 | 10-Q | Skinvisible, Inc. Files 10-Q for Period Ending March 31, 2024 | low |
| Apr 16, 2024 | 10-K | Skinvisible, Inc. Files 2023 Annual Report on Form 10-K | medium |
Risk Profile
Risk Assessment: Of SKVI's 12 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $15,000 |
| Net Income | -$805,677 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $645 |
| Operating Margin | N/A |
| Total Assets | $133,623 |
| Total Debt | $10,138,047 |
Key Executives
- Chief Executive Officer
Industry Context
SKINVISIBLE, INC. operates in the topical, transdermal, and mucosal delivery system technology sector, targeting pharmaceutical, OTC, skincare, and cosmetic markets. The industry is characterized by innovation in drug delivery and formulation, with significant competition from established players and emerging technologies. Companies in this space often require substantial R&D investment and face regulatory hurdles.
Top Tags
10-Q (4) · pharmaceuticals (4) · Going Concern (2) · Liquidity Crisis (2) · Biotechnology (2) · Pharmaceuticals (2) · Penny Stock (2) · 10-K (2) · financial-statements (2) · financials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $805,677 | For the nine months ended September 30, 2025, indicating continued unprofitability. |
| Cash Balance | $645 | As of September 30, 2025, a critical low point for liquidity. |
| Total Liabilities | $10,138,047 | As of September 30, 2025, significantly outweighing assets and increasing from prior period. |
| Revenue | $15,000 | For the nine months ended September 30, 2025, showing no growth year-over-year. |
| Accumulated Deficit | $40,751,819 | As of September 30, 2025, highlighting substantial historical losses. |
| Common Shares Outstanding | 5,403,843 | As of November 13, 2025, indicating potential for further dilution. |
| Accrued Interest Payable | $3,212,969 | As of September 30, 2025, a significant component of current liabilities. |
| Accounts Payable and Accrued Liabilities | $1,156,656 | As of September 30, 2025, a substantial increase from December 31, 2024. |
| Total Stockholders' Deficit | $10,004,424 | As of September 30, 2025, reflecting negative equity. |
| Additional Shares Issuable | 82,346,405 | In connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2025, indicating massive potential dilution. |
| Cash at June 30, 2025 | $120 | Represents a 98.8% decrease from $10,336 at December 31, 2024, indicating severe liquidity issues. |
| Net loss for six months ended June 30, 2025 | $555,432 | Despite a slight improvement from $593,821 in 2024, it contributes to the accumulated deficit. |
| Accumulated deficit since inception | $40,501,574 | Highlights significant historical losses and raises 'going concern' doubts. |
| Revenue for six months ended June 30, 2025 | $10,000 | Stagnant revenue year-over-year, showing no growth in core business operations. |
| Total current liabilities at June 30, 2025 | $4,525,151 | Increased from $3,657,266 at December 31, 2024, exacerbating financial strain. |
Frequently Asked Questions
What are the latest SEC filings for Skinvisible, Inc. (SKVI)?
Skinvisible, Inc. has 12 recent SEC filings from Apr 2024 to Nov 2025, including 6 10-Q, 4 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SKVI filings?
Across 12 filings, the sentiment breakdown is: 2 bearish, 10 neutral. The dominant sentiment is neutral.
Where can I find Skinvisible, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Skinvisible, Inc. (SKVI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Skinvisible, Inc.?
Key financial highlights from Skinvisible, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SKVI?
The investment thesis for SKVI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Skinvisible, Inc.?
Key executives identified across Skinvisible, Inc.'s filings include Chief Executive Officer.
What are the main risk factors for Skinvisible, Inc. stock?
Of SKVI's 12 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Skinvisible, Inc.?
Forward guidance and predictions for Skinvisible, Inc. are extracted from SEC filings as they are enriched.